Taysha Gene Therapies (NASDAQ:TSHA) Insider Sukumar Nagendran Sells 200,000 Shares

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) insider Sukumar Nagendran sold 200,000 shares of the company’s stock in a transaction on Friday, April 10th. The shares were sold at an average price of $4.46, for a total value of $892,000.00. Following the completion of the transaction, the insider directly owned 1,136,410 shares in the company, valued at $5,068,388.60. This represents a 14.97% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sukumar Nagendran also recently made the following trade(s):

• On Monday, January 26th, Sukumar Nagendran sold 26,918 shares of Taysha Gene Therapies stock. The shares were sold at an average price of $4.61, for a total transaction of $124,091.98.
• On Friday, January 23rd, Sukumar Nagendran sold 89,132 shares of Taysha Gene Therapies stock. The shares were sold at an average price of $4.75, for a total transaction of $423,377.00.

Taysha Gene Therapies Stock Down 1.6%

NASDAQ:TSHA traded down $0.07 during trading hours on Monday, hitting $4.42. 1,583,658 shares of the stock traded hands, compared to its average volume of 2,666,011. The firm has a 50 day moving average price of $4.54 and a 200 day moving average price of $4.71. The company has a current ratio of 12.23, a quick ratio of 12.23 and a debt-to-equity ratio of 0.20. Taysha Gene Therapies, Inc. has a fifty-two week low of $1.13 and a fifty-two week high of $6.02. The firm has a market cap of $1.27 billion, a price-to-earnings ratio of -13.00 and a beta of 1.10.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its earnings results on Thursday, March 19th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.03. The firm had revenue of $5.49 million for the quarter, compared to analyst estimates of $1.89 million. Equities research analysts anticipate that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current year.

Institutional Investors Weigh In On Taysha Gene Therapies

A number of hedge funds have recently bought and sold shares of the company. Intech Investment Management LLC boosted its holdings in Taysha Gene Therapies by 3.6% during the fourth quarter. Intech Investment Management LLC now owns 71,069 shares of the company’s stock valued at $391,000 after acquiring an additional 2,443 shares during the period. Chicago Partners Investment Group LLC boosted its holdings in Taysha Gene Therapies by 1.5% during the fourth quarter. Chicago Partners Investment Group LLC now owns 166,541 shares of the company’s stock valued at $916,000 after acquiring an additional 2,504 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Taysha Gene Therapies by 26.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,311 shares of the company’s stock valued at $73,000 after acquiring an additional 2,765 shares during the period. Virtus Investment Advisers LLC boosted its holdings in Taysha Gene Therapies by 7.0% during the fourth quarter. Virtus Investment Advisers LLC now owns 45,946 shares of the company’s stock valued at $253,000 after acquiring an additional 3,008 shares during the period. Finally, Xponance Inc. boosted its holdings in Taysha Gene Therapies by 29.1% during the third quarter. Xponance Inc. now owns 16,575 shares of the company’s stock valued at $54,000 after acquiring an additional 3,738 shares during the period. 77.70% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on TSHA shares. Canaccord Genuity Group boosted their price target on shares of Taysha Gene Therapies from $14.00 to $17.00 and gave the company a “buy” rating in a report on Monday, April 6th. Raymond James Financial restated a “strong-buy” rating and set a $13.00 price target on shares of Taysha Gene Therapies in a report on Tuesday, January 6th. Wall Street Zen upgraded shares of Taysha Gene Therapies from a “sell” rating to a “hold” rating in a report on Saturday, March 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Taysha Gene Therapies in a report on Friday, March 27th. Finally, Truist Financial upgraded shares of Taysha Gene Therapies to a “strong-buy” rating in a report on Wednesday, March 25th. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $11.64.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.